Collagen fibres in suspension have been shown to inhibit adenylate cyclase in human platelet preparations. Direct inhibition by collagen fibres was observed when intact platelets were used, although secondary events such as ADP secretion or prostanoid formation were important contributors to the inhibition of adenylate cyclase after treatment of platelets with collagen. The nature of the direct inhibition caused by collagen has been investigated in platelet membrane preparations, with the following results. (1) Collagen fibres inhibit platelet membrane adenylate cyclase in a dosedependent manner. (2) Inhibition of adenylate cyclase by thrombin, adrenaline or collagen fibres could be abolished in the presence of guanosine 5'-[/3-thio]diphosphate; half-maximal inhibition was obtained at about 100 #M for the inhibitory action of thrombin, and at about 500 /M for that of either adrenaline or collagen. (3) The action of each ligand was blocked to a similar extent by pertussis-toxin treatment of the platelet membranes. Taken together, these results indicate that the action of collagen, like that of thrombin and adrenaline, is G-protein-dependent. (4) Inhibition of adenylate cyclase by collagen fibres was additive with that caused by adrenaline, but co-operative with that caused by thrombin, suggesting that inhibitory pathways exists for collagen and adrenaline which are distinct from, but interactive with, that for thrombin. (5) Modification of the collagen fibres by pepsin treatment attenuated the effects of collagen, whereas heatdenaturation of the collagen fibres completely abolished their effects. These data suggest that the effects of collagen are specific, and depend on the detailed structure of the collagen fibres.
INTRODUCTION
Collagen is a potent activator of platelets, causing secretion from the platelet granules and aggregation of platelet suspensions, and collagens of the blood vessel walls are considered to be primary physiological stimuli for the haemostatic process (see Rink & Hallam, 1984) . The collagen-platelet interaction is also considered important in the pathology of the blood vessel wall (Barnes, 1988) . Collagen is known to interact with transmembrane signalling pathways in platelets, although a precise understanding is lacking of the receptor populations on the platelet surface responsible for binding collagen and their subsequent activation of guanine-nucleotide-binding proteins (Gproteins) and effector enzymes (for a detailed review of this topic, see Siess, 1989) . The platelet is controlled by the balance of membrane-bound signalling pathways. Phospholipases are considered crucial to the activatory process in platelets, with phospholipase A2-like activity in response to such agents as collagen and thrombin leading to the formation of thromboxane A2, which is itself a potent activatory stimulus. Phospholipase C activities may also be stimulated by collagen, with consequent increases in internal Ca2+ concentration and protein kinase C activity in platelets (see Kroll & Schafer, 1989) . These pathways are considered important primary components of the platelet activation process; subsequent secretion of the platelet granule contents leads to amplification of these events, since the granules contain, for example, ADP and 5-hydroxytryptamine (5HT), both of which have activatory properties (see Zucker & Nachmias, 1985) .
These signals are counterbalanced in the circulating platelet by the adenylate and guanylate cyclase pathways. These are stimulated principally by prostacyclin and nitric oxide respectively, which may be derived primarily from the vascular endothelium (see Siess, 1989) . It is considered that the activatory process in platelets is facilitated by inhibition of adenylate cyclase, although an absolute requirement for such inhibition before platelet activation can occur is not proven. The platelet products, ADP, 5HT and thromboxane A2, which are secreted during activation, together with thrombin, generated during the coagulation process, are each inhibitory towards adenylate cyclase (see Tremblay & Hamet, 1987) . It has been proposed that collagen itself is also a direct inhibitor, although there is little detailed evidence for this. For example , Chiang et al. (1975) used collagen to promote aggregation and secretion of 5HT in platelets, and found a concomitant decrease in their cyclic AMP content. The explicit purpose of their experiments was to examine secretion, and the lower levels of cyclic AMP observed in the presence of collagen and collagen-derived materials may simply have reflected inhibition of adenylate cyclase secondary to this process. Platelet activation also leads to extreme changes in their morphology, and it is not certain that such physico-chemical alterations in the platelet membrane do not affect the adenylate cyclase system; the membrane environment is known to be an important determinant of adenylate cyclase activity (Houslay & Gordon, 1983) .
In another study, Misselwitz et al. (1987) partially controlled for the effects of secretion from whole platelets by including indomethacin, a cyclo-oxygenase inhibitor, together with rather low levels of phosphocreatine and creatine kinase, an ADPscavenger system, and, although they observed decreased cyclic AMP levels after adhesion to collagen-coated substrates, this might have resulted from inhibition of adenylate cyclase by 5HT released from endogenous sources, or from increased phosphodiesterase activity.
More compelling evidence for a direct effect of collagen was provided by the early study by Salzman & Levine (1971) , who used freeze-permeabilized platelets without further separation of membranes to demonstrate inhibition of adenylate cyclase. For a direct effect of collagen to be inferred from that work it is necessary, and seems likely, that other secondary events such as thromboxane generation and granule secretion were completely uncoupled from the primary collagen binding by permeabilization of the platelets. However, that study pre-dates the present understanding of the inhibitory pathways of adenylate cyclase (see Northup, 1985) , so that more detailed experiments are necessary to establish the precise effects of collagen on the inhibition of platelet adenylate cyclase.
The adenylate cyclase assay is both convenient and reproducible. In the study described below, we sought to determine whether it could be used to reflect early and direct events following the interaction between platelet membranes and collagen. Firstly, we wished to establish the nature of the proposed inhibition of adenylate cyclase using human platelet membranes and to see whether it was susceptible to alterations in collagen structure which might ultimately enable us to test domains of the collagen molecule for interaction with the platelet surface.
The signalling pathways referred to above are activated by ligands binding to specific receptors on the platelet surface. It is well established that this may lead to the activation of specific classes of trimeric G-proteins, which in turn modulate the activity of specific effector enzymes. These events lead to changes in the cytosolic environment and to changes in platelet function, often the result of altered protein kinase activity. Adenylate cyclase is the best-characterized of these signalling pathways, and positive responses of adenylate cyclase are known to be mediated by Gs, its stimulatory G-protein (Gilman, 1987) . In contrast, signals inhibitory to adenylate cyclase (see Northup, 1985) in platelets are considered, for adrenaline at least, to be mediated by G.2 (Simonds etal., 1989) one of several genetically distinct inhibitory G-proteins (see Milligan, 1988) which share the property that their action is blocked by the covalent modification introduced by pertussis toxin. Such pertussis-toxin-sensitive G-proteins have also been implicated in the activation of other signalling pathways, such as phospholipase A2 (see Axelrod et al., 1988 ) and phosphoinositidase C, although for the latter this remains a contentious issue, since no G-protein has been identified to date which performs this function in all cell types. The G-protein population of the platelet is highly complex; as well as G., it is known to contain Gi2, G,3 (Simonds et al., 1989) , Gz (Carlson et al., 1989) , together with a plethora of 20-25 kDa guaninenucleotide-binding proteins (Bhullar & Haslam, 1987; Ohmori et al., 1989) as well, perhaps, as a GO-like entity (Kajiyama et al., 1990) . Many of the signalling pathways activated in platelets by collagen are considered to be G-protein-dependent, although in very few studies has activation of G-proteins by collagen been demonstrated. Where this has been described (e.g. Lapetina et al., 1986; Walker & Bourgignon, 1990) (Zijenah et al., 1990) . Heat denaturation was performed by immersion of a polypropylene tube containing collagen fibres at 1 mg/ml in a boiling-water bath for 2 h. After this, the denatured collagen was kept at 60°C until needed, and then dispensed into adenylate cyclase assay tubes at 30°C immediately before use. This procedure was adopted to minimize renaturation ofcollagen which might have occurred on cooling.
Platelet membrane preparation Platelet concentrates were obtained from the Regional Blood Transfusion Service, Hills Road, Cambridge, U.K., within 24 h of collection. Typically three packs of platelets were used for a single preparation by the method used previously in this laboratory (Stein & Martin, 1983; Farndale et al., 1987) , and batches were stored at -80°C until required. Membrane protein was measured by the method of Lowry et al. (1951) .
Cyclic AMP assay
Platelets from a single pack of concentrate were pelleted by centrifugation at O000 g for 15 min and resuspended in 145 mMNaCl/5mM-KCI/ lOmM-glucose/ ImM-MgSO4/0.5mM-EGTA/ 10 mM-Hepes/NaOH, pH 7.4, containing BSA at 3.5 g/l, then counted and diluted to 5 x 108 platelets/ml. IBMX was added from an ethanolic stock solution (0.1M) to 0.1 mm final concentration, and theplatelet suspension was held at 37°C for 5 min. Incubations were started by adding about 150 ,1 of platelets to PGE1 (with other additions in the same buffer) and 20 j1 of 0.01M-acetic acid with or without collagen fibres at 1000 4g/ml. After suitable times, the reaction was stopped by transferring the tubes to a boiling-water bath for 5 min, centrifuging and taking 50
,u1 portions of the supernatants for assay by a modification (Farndale et al., 1992) of the competitive binding assay of Brown et al. (1971) .
Adenylate cyclase assay
This was conducted as we have described previously (Farndale et al., 1987; Wadman et al., 1991 ,ul.
The reaction was stopped with100 ,1 of 2% (w/v) SDS containing 40 mMrATP and 1.4mM-cyclic AMP. The products wereseparated by the method of Salomon et al. (1974) and quantified by liquid-scintillation counting.
Adenylate cyclase activity in four membrane preparations Table 1 shows the properties of four preparations of human platelet membranes. These prvfiaan beae sim larly; each showed about a 10-fold increase in adenylate cyclase activity Table 1 . Adenylate cyclase activity in four membrane preparations
The adenylate cyclase activity of about 50 ,sg of membrane protein per assay tube from each of four platelet membrane preparations was determined during 20 min as described in the Experimental section. All assays were performed in the presence of 10 uM-GTP, 0.1 uM-PGE,, 10 ItMadrenaline (Adr) or thrombin (1 unit/ml; Thr) were included as indicated in the when 0.1 /tM-PGE, was included in the assay, and each was substantially inhibited by 10 4uM-adrenaline or 1 unit of thrombin/ml. This was taken to indicate that the receptor populations of the preparations were actively coupled to both stimulation and inhibition of adenylate cyclase. In the work described below, at least four preparations were used individually in each experimental procedure, unless indicated otherwise in the legends. Where a single experiment is used to illustrate the results, it was representative of the performance of the four individual preparations.
Platelet aggregation
Blood (18 ml), drawn from the antecubital vein of a volunteer who had not taken aspirin recently, was anticoagulated with 2 ml of 3.8 % (w/v) trisodium citrate. Platelet-rich plasma (PRP) was prepared by centrifugation at 1000 g for 1 min, and platelet-poor plasma (PPP) was prepared by centrifuging for a further 10 min. The reactions were conducted as we have described previously (Fitzsimmons et al., 1986) , by adding 3,Il of collagen fibre suspensions at known concentration to 150 ,1 of PRP in a stirred aggregometer (Bryston) cuvette. The chart recorder output was calibrated by using PPP and PRP, and aggregation was measured as an increase in light transmittance.
with 0.1 uM-prostacyclin. This experiment suggested that receptors for both PGE1 and collagen were functional in the platelets used in this study after storage for 24 h.
Dependence of inhibition of platelet adenylate cyclase on secreted products
To determine whether prostanoid formation was an intermediate in the inhibition of adenylate cyclase by collagen, platelet suspensions were incubated at 37°C with or without 1O /uMindomethacin together with IBMX as above for 5 min before mixing with PGE1 and other additions. In each of two such experiments, the inhibition of cyclic AMP production caused by the addition of collagen was about 10 % less when indomethacin was included.
To test whether the platelet granule contents also had a role in these events, experiments were conducted on three separate preparations of platelets incubated with IBMX and 10 ItMindomethacin as above. Levels of ADP (2 #M) which were maximally inhibitory (Cooper & Rodbell, 1979) and of ATP (100,M) which were supramaximally antagonistic towards the ATP receptor (Cusack & Hourani, 1982) were included in some incubations, and the effect of collagen (100 ,g/ml) was de-RESULTS Collagen-stimulated platelet aggregation Fig. 1 shows the capacity of the bovine tendon type I collagen fibres used throughout this study to cause aggregation in freshly prepared human PRP. A near-maximal response was obtained with collagen at 4 /ug/ml. These data show that the suspension of collagen fibres used for all the experiments described here was an active aggregatory preparation.
Inhibition of cyclic AMP production in whole platelets Fig. 2 shows the increase in cyclic AMP content of washed human platelets stimulated by the addition of 0.1 ,uM-PGE1 in the presence of 0.1 mM-IBMX, an inhibitor of cyclic AMP phosphodiesterase. The control curve shows a rapid and significant rise to about 10 times the resting cyclic AMP level; the latter parameter was re-measured at the end of the time course, and was not significantly altered from the initial level. The inclusion of collagen at 100 ,zg/ml with 0.1 ,IM-PGE1 exerted a marked inhibitory effect on the generation of cyclic AMP in these platelets, so that a plateau level about 6 times basal was reached. The inhibition by collagen occurred rapidly, being significant at the earliest time point tested. The control cyclic AMP levels, with PGE1 alone, are of the same order as those obtained by Karniguian et NaCI/5mM-KCI/ 1 0mM-glucose/ 1 mM-MgSO4/0.5rmM-EGTA/ 10 mM-Hepes/NaOH, pH 7.4, containing BSA at 3.5 g/l and 100 /SM-IBMX) were added to 0.1 ,uM-PGE1 with or without collagen (100 jug/ml), mixed and incubated at 37°C for the indicated times. Samples were then boiled for 5 min, centrifuged, and cyclic AMP was assayed as described in the Experimental section. Data represent means+S.E.M. from triplicate determinations for control (-) and collagen-treated (0) platelets. were performed on platelet membrane preparations. Fig. 3 shows the inhibition of PGEl-stimulated adenylate cyclase caused in platelet membranes by increasing doses of collagen. Individual preparations of platelet membranes each showed significant inhibition above a collagen level of about 30 ,Ig/ml. In the experiment shown, the concentration of collagen fibres was not tested above 100 lg/ml, but separate experiments indicated that inhibition continued to increase at least as far as 200 ug/ml, and appeared to be proportional to the collagen concentration used. Varying the platelet membrane concentration between 10 and 100 lg of protein per assay did not affect the inhibition of adenylate cyclase caused by collagen at 100 ,g/ml (results not shown).
Time-dependence of inhibition Fig. 4 shows that the inhibition of adenylate cyclase by collagen at 100 ,ug/ml occurred without delay, and that the level of inhibition did not change significantly during 20 min incubation, although, since adenylate cyclase activity appeared to decline somewhat towards the end of the experiment, optimum separation of the curves was obtained after 15 min. For all subsequent experiments, therefore, the adenylate cyclase assay was conducted for 15 min.
Role of prostanoids and ADP in the action of collagen Since our experiments with whole platelets demonstrated a partial role for both prostanoids and ADP in the action of collagen on adenylate cyclase, it is important to determine whether these factors are also active in the platelet membrane experiments, although at the outset we considered it improbable that secondary events such as prostanoid formation and secretion would remain actively coupled to collagen receptors after the membrane preparation process. To test this possibility, we conducted adenylate cyclase assays both in the presence of 1O,sM-adenosine 5'-[fl-thio]diphosphate to saturate ADP receptors (Cooper & Rodbell, 1979) , and with 500 ,sM-ATP further to antagonize ADP, which potentially might be released by the addition of collagen in the event that the granule system were Adenylate cyclase assays were performed as described in the legend to Fig. 3 by the inclusion of 10 #uM-indomethacin or 1 mM-EGTA in the assays, which would block the stimulation of prostanoid formation and phospholipase activity respectively. We conclude that the effects of collagen under these circumstances were direct.
Inhibition by adrenaline with and without collagen Fig. 5 shows the inhibition of platelet adenylate cyclase observed in the presence of increasing doses of adrenaline, both with and without collagen at 100 ,ug/ml. This experiment showed the expected sigmoid curve for adrenaline alone, with nearmaximal inhibition at 10 /sM-adrenaline and no further inhibition occurring as the concentration was increased to 1 mm. The addition of collagen caused further inhibition at all doses of adrenaline, so that the adrenaline inhibition curve was displaced downwards by the inclusion of collagen. Hence, with even maximal levels of adrenaline, further inhibition could be obtained by adding collagen.
Inhibition by thrombin with and without collagen Fig. 6 shows the inhibitory response of platelet membranes to increasing doses of thrombin with and without collagen at 100 /ug/ml. The control curve has a complex shape of closely similar form to that described by Aktories & Jakobs (1984) . The curve obtained with thrombin concentrations below about 1 unit/ ml was sigmoid, similar to that obtained with adrenaline, but higher doses caused an additional, linear, decline in adenylate cyclase activity. This phase of the thrombin effect was found by Aktories & Jakobs (1984) to be independent of GTP, and was hence considered non-specific. In the presence of collagen, low doses of thrombin (which alone were without effect) caused a significant additional inhibition of adenylate cyclase activity over that caused by collagen alone; for example, thrombin at 0.03 unit/ ml alone was not significantly inhibitory, but the inclusion of thrombin at 0.03 unit/ml with collagen at 100 ,ug/ml caused a significant further decrease in adenylate cyclase activity. This Vol. 282 collagen fibres Adenylate cyclase assays were performed on 29 ,g of platelet membrane protein per assay as described in the legend to Fig. 3. [Thrombin] was varied as indicated, and assays were performed with (0) or without (A) collagen fibres (final concn. 100 ,ug/ml). Data are means +S.E.M. from four replicates from one experiment, and similar results were obtained with three other membrane preparations.
suggested that some synergism between collagen and thrombin existed in the inhibition of platelet adenylate cyclase, and is a qualitatively different result from that obtained with adrenaline.
At thrombin doses close to the point of inflection of the control curve, i.e. about I unit/ml, corresponding to the limit of [Collagen] (pg/ml) presence of the two lowest doses of thrombin tested, 0.003 and 0.01 unit/ml, was to cause greater inhibition of adenylate cyclase (about 30 %). As thrombin dose increased, this proportion decreased rapidly, so that at 30 units/ml the additional effect of collagen was negligible. These data were negatively correlated (r = 0.93, P < 0.01), and again suggest co-operative and saturable inhibition of adenylate cyclase by thrombin and collagen, whereas no such interaction was observed with adrenaline. (El, control) or collagen fibres+thrombin at 0.01 unit/ml (0). Adenylate cyclase activity was determined as described in the legend to Fig. 3 . Each data point, the inhibition of adenylate cyclase activity calculated as a percentage of activity obtained in the absence of collagen, represents the mean inhibition + S.E.M. obtained from the mean values from four experiments, each with four replicates.
GTP-dependent inhibition, collagen caused further inhibition of adenylate cyclase, but at higher doses of thrombin no significant inhibition was obtained by the addition of collagen.
Relative inhibition by adrenaline and thrombin+ collagen Fig. 7 replots the mean data from four experiments, each similar to those depicted in Figs. 5 and 6, to emphasize the difference in behaviour of adrenaline and thrombin in the presence of collagen; the graph shows the percentage inhibition of platelet membrane adenylate cyclase caused by collagen fibres in the presence of increasing concentrations of either adrenaline or thrombin. The difference in the properties of the two ligands is clearly discernible: at low adrenaline concentration the effect of collagen was to cause about a 20 % decrease in adenylate cyclase activity, and with increasing adrenaline concentration this proportion did not change significantly (assessed by linear regression, r = 0.8, P < 0.1), although it appeared to increase somewhat. In marked contrast, the effect of collagen in the Effect of low Ithrombin] on collagen dose-response curve To test this interactive inhibition further, the converse experiment was conducted on each of four platelet membrane preparations. Collagen fibre concentration was varied in the presence and absence of a low dose (0.01 unit/ml) of thrombin, which was inactive on its own (see Fig. 6 ). Fig. 8 gives the pooled results of the four experiments, and shows the expected linear inhibition of adenylate cyclase by collagen alone. In the presence of thrombin, the curve shows a more rapid onset of inhibition with increasing collagen dose, but above 30 jig/ml the two curves appeared convergent, since the data were not significantly different. The apparent effect of thrombin was to increase the sensitivity of platelet adenylate cyclase to collagen: collagen at 10 ,ug/ml in the presence of thrombin caused the same inhibition of adenylate cyclase as collagen at 30 ,ug/ml without thrombin.
Effect of pertussis toxin on inhibition of adenylate cyclase
To examine the role of G-proteins involved in these events, platelet membranes were incubated with 1 mM-NADI and activated pertussis toxin (3 ,tg/ml) for 30 min, and then their susceptibility to inhibitors of adenylate cyclase was tested. The data from one of four such experiments is shown in Table 3 , showing that blockade by pertussis-toxin treatment of the inhibitory effects of collagen, adrenaline or thrombin was not complete. This presumably reflected incomplete ADP-ribosylation of the Gi-like complement of the platelet membranes under the conditions tested. However, the relative activity of each of the inhibitors was attenuated to a rather similar extent, i.e. about 45 %. This experiment indicated that the action of collagen is likely to be G-protein-mediated and, as might be expected, (Eckstein et al., 1979) . Structural requirements for the effects of collagen In a preliminary investigation of the structural determinants for the inhibition of platelet adenylate cyclase by collagen, membranes were treated in two sets of experiments with collagen fibres in suspension (100,ug/ml) alongside either collagen fibres derived from the same preparation which had been treated with pepsin (to remove the non-helical N-and C-terminal telopeptides from the collagen fibres) or collagen fibres which had been denatured by heating to 100°C for 2 h. Both treatments impaired the ability of collagen to inhibit adenylate cyclase; pepsin treatment halved the effect of collagen at 100 ,ug/ml, but lower doses of the pepsin-treated material, tested down to 10 g/ml, were without significant effect. In contrast, heat-denatured collagen was without significant inhibitory activity (results not shown). Synergism between thrombin and collagen might then occur as these two activated G-proteins converge upon adenylate cyclase.
Evidence for more complex schemes for the action of thrombin on platelets involving the activation of multiple G-proteins has been produced by others (e.g. Houslay et al., 1986) . Lapetina (1990) proposed a scheme for the activation by thrombin of phosphoinositidase C in platelets in which the activation of G12 also involved a 20 kDa guanine-nucleotide-binding protein, Raplb. Our data might be consistent with these previous proposals, and indicate that thrombin activates a G-protein having a lower affinity for GTP that either G. or G12.
Although a substantial literature describes the activation of platelet signalling pathways by collagen, little is known about the identity of G-protein activated directly by the primary event of collagen binding to to its receptor. This in part results from the lack of cell-free systems in which signalling pathways other than adenylate cyclase may be examined. The present work provides direct evidence for a pertussis-toxin-sensitive G-protein in the signal-transduction pathway activated by collagen. The identity of the G-protein involved must await further study, although it appears to be kinetically indistinguishable from the G,2 thought to mediate the effect of adrenaline in platelet adenylate cyclase (Simonds et al., 1989) .
Many authors have used high levels of collagen to demonstrate effects on other platelet signalling pathways; it is not unusual for concentrations in excess of 10 ug/ml to be applied to these systems (e.g. Salzman & Levine, 1971; Chiang et al., 1975; Lapetina et al., 1986; Pollock et al., 1986; Walker & Bourgignon, 1990) . It should be noted that the concept of concentration cannot easily be applied to collagen, since in its physiological state and as applied here it exists as an extensively aggregated fibre. The majority of the mass of the collagen is likely to lie within the fibre, but it is only the surface of the fibre which can Vol. 282 interact with the platelet. It is difficult to compare doses of collagen between different experimental studies without a detailed knowledge of the state of aggregation of the collagens used.
However, it is clear within this study that the inhibitory response of platelet adenylate cyclase extends to at least a collagen level (100 ,ug/ml) well beyond that necessary to cause maximal platelet aggregation in PRP (-4 ,ug/ml), although the minimum collagen level causing detectable inhibition ofadenylate cyclase in the presence of thrombin may be of the same order as the latter. Several reasons might be advanced to explain this apparent discrepancy. Firstly, platelet aggregation is a highly cooperative event in which secretion of the platelet granule constituents, such as ADP, together with thromboxane production, plays an important amplifying role, which we have confirmed in the present study. The effects of these products have deliberately been avoided by using membrane preparations, so that the effects of exogenous materials may be observed directly. Secondly, it is possible that the platelet-collagen interaction involves other constituents of either plasma or platelet granules (such as fibrinogen, fibronectin, thrombospondin and von Willebrand factor), which have been substantially washed from the platelets during the preparation procedure. It is our experience (M. J. Barnes, unpublished work) that a fully aggregatory response of washed platelets can only be obtained with much higher doses of collagen than is needed for aggregation of platelets in PRP. This concept is supported by the work of Zijenah et al. (1990) , who demonstrated a role for plasma constituents in promoting Mg2+-independent platelet adhesion to bovine tendon collagen type I fibres.
Our preliminary data suggest that the triple-helical or fibrous state of the native collagen is essential for the inhibition of adenylate cyclase by collagen, since heat-denatured collagen fibres were inactive. The minor modification of collagen structure (removal of the non-helical N-and C-terminal telopeptides) caused by pepsin treatment may also be important in determining the extent or consequences of collagen binding to the platelet membrane. These findings are consistent with the effects of collagen on platelet aggregation, where previous studies have shown that heat-denatured collagen was inactive (see Santoro & Cunningham, 1980) and pepsin treatment of collagen fibres impaired their aggregatory activity (M. J. Barnes, unpublished work) . This interpretation of our data should be treated with some caution, since it is plausible that other constituents of the collagen preparation may be important and are also removed or denatured by the treatments applied here. However, it can be concluded from the present study that the inhibitory action of collagen on platelet adenylate cyclase provides a system in which the structural requirements of collagen for interaction with the platelet surface might readily be investigated.
